ASH 2019 Annual Meeting Highlights in Acute Myeloid Leukemia
Please complete Pre-test
Chapter 1 of 5
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, you will view video highlights from the 2019 American Society of Hematology (ASH) Annual Meeting. Experts share their insights on a variety of abstracts, covering topics including, but not limited to: IDH2 mutations, quizartinib in patients with relapsed/refractory (R/R) AML, and venetoclax-based therapies in newly-diagnosed and R/R AML.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Summarize the efficacy and safety data from clinical trials investigating new and emerging novel therapies and treatment strategies in patients with acute myeloid leukemia (AML)
- Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in AML
- Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in AML
Chapter 1: Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory AML - Jorge E. Cortes, MD
Chapter 2: Encouraging Clinical Profile of IMG632 and Updated Results from Venetoclax in Combination with Idasanutlin- Naval Daver, MD
Chapter 3: PRIMULA and ASCERTAIN: Updates from Two Potentially Practice-changing Studies- Guillermo Garcia-Manero, MD
Chapter 4: Mutations in Patients with R/R AML Who Received Gilteritinib or in Response to Quizartinib or Salvage Chemotherapy - Alexander Perl, MD;
Chapter 5: Relapse Following Ivosidenib Monotherapy in Patients with IDH1 Mutant R/R AML and Enasidenib plus Azacitidine Improves CR and Overall Response Rates in ND AML - Eytan M. Stein, MD
Instructions for Participation and Credit
This activity is eligible for credit through January 3, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Jorge E. Cortes, MD
Georgia Cancer Center
Dr. Jorge Cortes received his medical degree from the Universidad Nacional Autonoma de Mexico, Mexico City. He recently joined Augusta University as the Director of the Georgia Cancer Center in Augusta, Georgia, after being at The University of Texas MD Anderson Cancer Center since 1991 where he had taken on many roles in the Department of Leukemia, Division of Cancer Medicine; including Deputy Department Chair, Chair of AML and CML Sections, Professor of Medicine and Internist. He holds the title of Jane and John Justin Distinguished Chair in Leukemia Research and is the Leukemia Fellowship Program Director.
As Director, Dr. Cortes continues the Georgia Cancer Center’s mission of obtaining National Cancer Institute (NCI) designation, while keeping the mission of ‘reducing the burden of cancer in the State of Georgia and across the globe through superior care, innovation and education’ at the forefront of all endeavors. He has over 230 grants and contracts where he was principal investigator. Dr. Cortes has authored nearly 1,000 peer-review original research articles with numerous other accolades towards his name and practice.
Naval Daver, MD
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Dr. Naval Daver received his medical degree from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine in Houston, Texas. He is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
A clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis, Dr. Daver is the co/principal investigator for more than 25 ongoing clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis, and is conducting a number of these trials. Dr. Daver has published more than 100 peer-reviewed manuscripts. He has also authored numerous abstracts at national and international conferences.
Guillermo Garcia-Manero, MD
Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research
Chief, Section of Myelodysplastic Syndromes
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Dr. Guillermo Garcia-Manero received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London. He completed his internship and residency in internal medicine at Thomas Jefferson University Hospital in Philadelphia. He continued his training with a fellowship in hematology and medical oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center, and Thomas Jefferson University Hospital, where he served as chief fellow. Dr. Garcia-Manero is currently a Professor in the Department of Leukemia and the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research at the University of Texas MD Anderson Cancer Center. He also serves as the Chief of the Section of Myelodysplastic Syndromes, Vice Chairman for Translational Research, Leader of the AML/MDS Moon Shot Program, and Program Director of the Leukemia Fellowship Program.
Dr. Garcia-Manero’s focus is on understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for these patients. His work has been funded by NIH, DoD, LLS, CPRIT, and the MDS/AML Moon Shot project. He is currently PI/Co-PI on over 25 active AML/MDS clinical trials and has coauthored more than 682 manuscripts. Dr. Garcia-Manero directs one of the largest single institution units for patients with MDS and maintains one of the busiest clinics at MD Anderson. He has trained over 100 fellows and post-doctoral fellows and has been a speaker at multiple national and international forums. He has received numerous awards, including the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research and the Emil J. Freireich Award for Excellence in Translational Research. Dr. Garcia-Manero has also been recognized as one of the Best Doctors in America each year since 2007.
Alexander Perl, MD
Associate Professor of Medicine
Abramson Cancer Center
University of Pennsylvania
Dr. Alexander Perl is a member of the leukemia program at the Abramson Cancer Center of the University of Pennsylvania, where he is an Associate Professor of Medicine. His particular expertise is in FLT3 inhibition as a therapeutic strategy for acute myeloid leukemia, clinical trials, and mechanisms of resistance to tyrosine kinase inhibitors.
Eytan M. Stein, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.
Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-004-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-004-113
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jorge Cortes has received honoraria as a consultant and grant support related to research activities from FORMA Therapeutics, Inc. and Jazz Pharmaceuticals plc.
Dr. Naval Daver has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Karyopharm Therapeutics, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and Sunesis. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Inc., GlycoMimetics, Inc., ImmunoGen, Incyte, Karyopharm, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.
Dr. Guillermo Garcia-Manero has received honoraria as a consultant from Amphivena Therapeutics, Inc., Astex Pharmaceuticals, and Celgene Corporation. He has received grant support related to research activities from AbbVie Inc., Amphivena, Astex, Celgene, H3 Biomedicine Inc., Helsinn Healthcare SA, Merck & Co., Inc., Novartis AG, and Onconova Therapeutics.
Dr. Alexander Perl has received honoraria as a consultant from Arog Pharmaceuticals, Inc., Asana BioSciences, LLC., Astellas Pharma US, Inc., Daiichi Sankyo, Inc., Novartis AG, and NewLink Genetics Corporation.
Dr. Eytan Stein has received honoraria related to formal advisory activities from Agios, Amgen Inc., Astellas Pharma US, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Genentech, Inc., Novartis AG, PTC Therapeutics, Seattle Genetics, Inc., and Syros Pharmaceuticals, Inc. He has received grant support related to research activities from Agios, Amgen, Bayer AG, BioTheryX, Inc., Celgene, and Syndax Pharmaceuticals, Inc. He also owns significant holdings in Auron Therapeutics.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
- Chapter 1: Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory AML – Run Time: 09:49
- Chapter 2: Encouraging Clinical Profile of IMG632 and Updated Results from Venetoclax in Combination with Idasanutlin – Run Time: 10:45
- Chapter 3: PRIMULA and ASCERTAIN: Updates from Two Potentially Practice-changing Studies – Run Time: 06:21
- Chapter 4: Mutations in Patients with R/R AML Who Received Gilteritinib or in Response to Quizartinib or Salvage Chemotherapy – Run Time: 06:55
- Chapter 5: Relapse Following Ivosidenib Monotherapy in Patients with IDH1 Mutant R/R AML and Enasidenib plus Azacitidine Improves CR and Overall Response Rates in ND AML– Run Time: 09:21
- Assessment and Evaluation